Eli Lilly says it could pull tens of millions of dollars invested in Australian clinical trials unless the federal government dramatically cuts the time it takes to put new drugs onto the Pharmaceutical Benefits Scheme.
The warning from one of the drugmaker’s top executives, visiting Australia this week, builds on pressure from the powerful pharmaceutical lobby for better deals for the medicines they sell domestically and comes at the same time as Donald Trump prepares to place tariffs on drug imports.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。